Therapeutic Gallium Compounds - George Eby Research Institute
Therapeutic Gallium Compounds - George Eby Research Institute
Therapeutic Gallium Compounds - George Eby Research Institute
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
276 <strong>Therapeutic</strong> <strong>Gallium</strong> <strong>Compounds</strong><br />
77. P.T. Guidon Jr, R. Salvatori and R.S. Bockman, J. Bone Miner. Res., 8, 103–112<br />
(1993).<br />
78. L.G. Jenis, C.E. Waud, G.S. Stein et al., J. Cell. Biochem., 52, 330–336 (1993).<br />
79. P.T. Guidon Jr and R.S. Bockman, Clin. Res., 38, 328A (1990).<br />
80. V. Matkovic, G. Apseloff, D.R. Shepard et al., Curr. Ther. Res., 50, 247–254<br />
(1991).<br />
81. C. Whitacre, G. Apseloff, K. Cox et al., J. Neuroimmunol., 39, 175–182 (1992).<br />
82. E.H. Huang, D.M. Gabler, M.E. Krecic et al., Transplantation, 58, 1216–1222<br />
(1994).<br />
83. N. Makkonen M.-R. Hirvonen, K. Savolainen et al., Inflamm. Res., 44, 523–528<br />
(1995).<br />
84. D. Mullet, X. Bian, G.W. Cox et al., FASEB J., 9, A944 (1995).<br />
85. J.A. Thorson, K.M. Smith, F. Gomez et al., Cell. Immunol., 134, 126–137 (1991).<br />
86. F.S. Panagakos, E. Kumar, C. Venescar and P. Guidon, Biochimie, 82, 147–151<br />
(2000).<br />
87. M.C. Lobanoff, A.T. Kozhich, D.I. Mullet et al., Exp. Eye Res., 65, 797–801<br />
(1997).<br />
88. J.O. Flynn, D.V. Serreze, N. Gerber and E.H. Leiter, Diabetes, 41, 38A (1992).<br />
89. M.E. Krecic, D.R. Shepard, G. Apseloff et al., FASEB J., 9, A944 (1995).<br />
90. M.E. Krecic-Shepard, D.R. Shepard, D. Mullet et al., Life Sci., 65, 1359–1371<br />
(1999).<br />
91. C.G. Orosz, E. Wakely, S.D. Bergese et al., Transplantation, 61, 783–791 (1996).<br />
92. D.J. Straus, Semin. Oncol., 30(2), Suppl. 5, 25–33 (2003).<br />
93. A.D. Seidman, H.I. Scher, M.H. Heinemann et al., Cancer, 68, 2561–2565 (1991).<br />
94. E.D. Crawford, J.H. Saiers, L.H. Baker et al., Urology, 38, 355–357 (1991).<br />
95. P.A. Seligman, P.L. Moran, R.B. Schleicher and E.D. Crawford, Am. J. Hematol.,<br />
41, 232–240 (1992).<br />
96. J.H. Malfetano, J.A. Blessing and M.D. Adelson, Am. J. Clin. Oncol., 14, 349–351<br />
(1991).<br />
97. J.H. Malfetano, J.A. Blessing and H.D. Homesley, Am. J. Clin. Oncol., 18, 495–497<br />
(1995).<br />
98. J.H. Malfetano, J.A. Blessing, H.D. Homesley and P. Hanjani, Invest. New Drugs,<br />
9, 109–111 (1991a).<br />
99. H.I. Scher, T. Curley, N. Geller et al., Cancer Treat. Rep., 71, 887–893 (1987).<br />
100. A.Y. Bedikian, M. Valdivieso, G.P. Bodey et al., Cancer Treat. Rep., 62, 1449–1453<br />
(1978).<br />
101. R.P. Warrell Jr, R. Israel, M. Frisone et al., Ann. Intern. Med., 108, 669–674 (1988).<br />
102. B. Leyland-Jones, Semin. Oncol., 30(2), Suppl. 5, 13–19 (2003).<br />
103. F. Bertheault-Cvitkovic, J.-P. Armand, M. Tubiana-Hulin et al., Proc. 9th EORTC/<br />
National Cancer Inst. Symposium on New Drugs in Cancer Chemotherapy, p. 140<br />
(1996).<br />
104. R.P. Warrell Jr, W.K. Murphy, P. Schulman et al., J. Clin. Oncol., 9, 1467–1475<br />
(1991).<br />
105. R.P. Warrell Jr, D. Lovett, F.A. Dilmanian et al., J. Clin. Oncol., 11, 2443–2450<br />
(1993).<br />
106. R. Niesvizky, Semin. Oncol., 30(2), Suppl. 5, 20–24 (2003).<br />
107. V. Matkovic, G. Apseloff, D.R. Shepard and N. Gerber, Lancet, 335, 72–75 (1990).
Change language